COVID-19 and long-term impact on symptoms and Health-Related Quality of Life in Costa Rica: the RESPIRA cohort study.
Cohort study
Costa Rica
HRQoL
Health-Related Quality of Life
Middle-Income Country
PASC
PCC
Post-Acute Sequelae of SARS-CoV-2
Post-COVID Conditions
symptoms
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
received:
03
05
2024
accepted:
30
05
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
4
6
2024
Statut:
epublish
Résumé
Evidence continues to accumulate regarding the potential long-term health consequences of COVID-19 in the population. To distinguish between COVID-19-related symptoms and health limitations from those caused by other conditions, it is essential to compare cases with community controls using prospective data ensuring case-control status. The RESPIRA study addresses this need by investigating the lasting impact of COVID-19 on Health-related Quality of Life (HRQoL) and symptomatology in a population-based cohort in Costa Rica, thereby providing a robust framework for controlling HRQoL and symptoms. The study comprised 641 PCR-confirmed, unvaccinated cases of COVID-19 and 947 matched population-based controls. Infection was confirmed using antibody tests on enrollment serum samples and symptoms were monitored monthly for 6 months post-enrolment. Administered at the 6-month visit (occurring between 6- and 2-months post-diagnosis for cases and 6 months after enrollment for controls), HRQoL and Self-Perceived Health Change were assessed using the SF-36, while brain fog, using three items from the Mental Health Inventory (MHI). Regression models were utilized to analyze SF-36, MHI scores, and Self-Perceived Health Change, adjusted for case/control status, severity (mild case, moderate case, hospitalized) and additional independent variables. Sensitivity analyses confirmed the robustness of the findings. Cases showed significantly higher prevalences of joint pain, chest tightness, and skin manifestations, that stabilized at higher frequencies from the fourth month post-diagnosis onwards (2.0%, 1.2%, and 0.8% respectively) compared to controls (0.9%, 0.4%, 0.2% respectively). Cases also exhibited significantly lower HRQoL than controls across all dimensions in the fully adjusted model, with a 12.4 percentage-point difference [95%CI: 9.4-14.6], in self-reported health compared to one year prior. Cases reported 8.0% [95%CI: 4.2, 11.5] more physical limitations, 7.3% [95%CI: 3.5, 10.5] increased lack of vitality, and 6.0% [95%CI: 2.4, 9.0] more brain fog compared to controls with similar characteristics. Undiagnosed cases detected with antibody tests among controls had HRQoL comparable to antibody negative controls. Differences were more pronounced in individuals with moderate or severe disease and among women. PCR-confirmed unvaccinated cases experienced prolonged HRQoL reductions 6 months to 2 years after diagnosis, this was particularly the case in severe cases and among women. Mildly symptomatic cases showed no significant long-term sequelae.
Sections du résumé
BACKGROUND
BACKGROUND
Evidence continues to accumulate regarding the potential long-term health consequences of COVID-19 in the population. To distinguish between COVID-19-related symptoms and health limitations from those caused by other conditions, it is essential to compare cases with community controls using prospective data ensuring case-control status. The RESPIRA study addresses this need by investigating the lasting impact of COVID-19 on Health-related Quality of Life (HRQoL) and symptomatology in a population-based cohort in Costa Rica, thereby providing a robust framework for controlling HRQoL and symptoms.
METHODS
METHODS
The study comprised 641 PCR-confirmed, unvaccinated cases of COVID-19 and 947 matched population-based controls. Infection was confirmed using antibody tests on enrollment serum samples and symptoms were monitored monthly for 6 months post-enrolment. Administered at the 6-month visit (occurring between 6- and 2-months post-diagnosis for cases and 6 months after enrollment for controls), HRQoL and Self-Perceived Health Change were assessed using the SF-36, while brain fog, using three items from the Mental Health Inventory (MHI). Regression models were utilized to analyze SF-36, MHI scores, and Self-Perceived Health Change, adjusted for case/control status, severity (mild case, moderate case, hospitalized) and additional independent variables. Sensitivity analyses confirmed the robustness of the findings.
RESULTS
RESULTS
Cases showed significantly higher prevalences of joint pain, chest tightness, and skin manifestations, that stabilized at higher frequencies from the fourth month post-diagnosis onwards (2.0%, 1.2%, and 0.8% respectively) compared to controls (0.9%, 0.4%, 0.2% respectively). Cases also exhibited significantly lower HRQoL than controls across all dimensions in the fully adjusted model, with a 12.4 percentage-point difference [95%CI: 9.4-14.6], in self-reported health compared to one year prior. Cases reported 8.0% [95%CI: 4.2, 11.5] more physical limitations, 7.3% [95%CI: 3.5, 10.5] increased lack of vitality, and 6.0% [95%CI: 2.4, 9.0] more brain fog compared to controls with similar characteristics. Undiagnosed cases detected with antibody tests among controls had HRQoL comparable to antibody negative controls. Differences were more pronounced in individuals with moderate or severe disease and among women.
CONCLUSIONS
CONCLUSIONS
PCR-confirmed unvaccinated cases experienced prolonged HRQoL reductions 6 months to 2 years after diagnosis, this was particularly the case in severe cases and among women. Mildly symptomatic cases showed no significant long-term sequelae.
Identifiants
pubmed: 38834971
doi: 10.1186/s12879-024-09450-6
pii: 10.1186/s12879-024-09450-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
557Subventions
Organisme : National Institute of Allergy and Infectious Diseases
ID : HHSN261201700012I / 75N91020F00001
Organisme : National Institute of Allergy and Infectious Diseases
ID : HHSN261201700012I / 75N91020F00001
Organisme : National Institute of Allergy and Infectious Diseases
ID : HHSN261201700012I / 75N91020F00001
Investigateurs
Alejandro Calderón
(A)
Karla Moreno
(K)
Melvin Morera
(M)
Roy Wong
(R)
Roberto Castro
(R)
Bernal Cortés
(B)
Rebecca Ocampo
(R)
Michael Zúñiga
(M)
Juan Carlos Vanegas
(JC)
Kaiyuan Sun
(K)
Marco Binder
(M)
Informations de copyright
© 2024. The Author(s).
Références
Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw open. 2021;4(10):e2128568.
doi: 10.1001/jamanetworkopen.2021.28568
pubmed: 34643720
pmcid: 8515212
Higgins V, Sohaei D, Diamandis EP, Prassas I. COVID-19: from an acute to chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci. 2021;58(5):297–310.
doi: 10.1080/10408363.2020.1860895
pubmed: 33347790
Callard F, Perego E. How and why patients made Long Covid. Soc Sci Med. 2021;268:113426.
doi: 10.1016/j.socscimed.2020.113426
pubmed: 33199035
pmcid: 7539940
Center for Disease Control and Prevention - National Center for Health Statistics. Post-COVID Conditions: Information for Healthcare Providers. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html .
U.S Department of Health and Human Services. Terms & Definitions: Long COVID Terms & Definitions. Available from: https://www.covid.gov/be-informed/longcovid/about#term .
Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. Jama. 2023;02114:1–13.
Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-7.
doi: 10.1016/S1473-3099(21)00703-9
pubmed: 34951953
Center for Disease Control and Prevention - National Center for Health Statistics. Long COVID or Post-COVID Conditions. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html .
Hirschtick JL, Titus AR, Slocum E, Power LE, Hirschtick RE, Elliott MR, et al. Population-Based Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (PASC) Prevalence and Characteristics. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2021;73(11):2055–64.
doi: 10.1093/cid/ciab408
National Health Service (United Kindom). Long-term effects of COVID-19 (long COVID). Available from: https://www.nhs.uk/conditions/covid-19/long-term-effects-of-covid-19-long-covid/ .
Munipalli B, Seim L, Dawson NL, Knight D, Dabrh AMA. Post-acute sequelae of COVID-19 (PASC): a meta-narrative review of pathophysiology, prevalence, and management. SN Compr Clin Med. 2022;4(1):90.
doi: 10.1007/s42399-022-01167-4
pubmed: 35402784
pmcid: 8977184
Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med. 2023;2(1). Available from: https://bmjmedicine.bmj.com/content/2/1/e000385 .
Evans RA, Leavy OC, Richardson M, Elneima O, McCauley HJC, Shikotra A, et al. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;2.
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2023; 17;401(10393):e21–33. Available from: https://doi.org/10.1016/S0140-6736(23)00810-3 .
Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226(9):1593–607.
doi: 10.1093/infdis/jiac136
pubmed: 35429399
Pérez-González A, Araújo-Ameijeiras A, Fernández-Villar A, Crespo M, Poveda E, Cabrera JJ, et al. Long COVID in hospitalized and non-hospitalized patients in a large cohort in Northwest Spain, a prospective cohort study. Sci Rep. 2022;12(1):3369.
doi: 10.1038/s41598-022-07414-x
pubmed: 35233035
pmcid: 8888560
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
doi: 10.1016/S0140-6736(20)30566-3
pubmed: 32171076
pmcid: 7270627
Montoy JCC, Ford J, Yu H, Gottlieb M, Morse D, Santangelo M, et al. Prevalence of Symptoms ≤12 Months After Acute Illness, by COVID-19 Testing Status Among Adults - United States, December 2020-March 2023. MMWR Morb Mortal Wkly Rep. 2023;72(32):859–65.
doi: 10.15585/mmwr.mm7232a2
pubmed: 37561663
pmcid: 10415002
Ware JEJ. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25(24):3130–9.
doi: 10.1097/00007632-200012150-00008
pubmed: 11124729
Barboza Solis C, Fantin R, Kelly-Irving M, Delpierre C. Physiological wear-and-tear and later subjective health in mid-life: Findings from the 1958 British birth cohort. Psychoneuroendocrinology. 2016;74:24–33.
doi: 10.1016/j.psyneuen.2016.08.018
pubmed: 27567118
Kaplan MS, Berthelot J-M, Feeny D, McFarland BH, Khan S, Orpana H. The predictive validity of health-related quality of life measures: mortality in a longitudinal population-based study. Qual Life Res. 2007;16(9):1539–46.
doi: 10.1007/s11136-007-9256-7
pubmed: 17899447
Otero-Rodriguez A, Leon-Munoz LM, Balboa-Castillo T, Banegas JR, Rodriguez-Artalejo F, Guallar-Castillon P. Change in health-related quality of life as a predictor of mortality in the older adults. Qual Life Res. 2010;19(1):15–23.
doi: 10.1007/s11136-009-9561-4
pubmed: 19946754
Loria V, Aparicio A, Hildesheim A, Cortés B, Barrientos G, Retana D, et al. Cohort profile: evaluation of immune response and household transmission of SARS-CoV-2 in Costa Rica: the RESPIRA study. BMJ Open. 2023;13(12):e071284.
doi: 10.1136/bmjopen-2022-071284
pubmed: 38070892
pmcid: 10729140
Fantin R, Barboza-Solís C, Santamaría-Ulloa C. Socioeconomic inequalities in cancer mortality: is Costa Rica an exception to the rule? Int J Cancer. 2020;147(5):1286–93.
doi: 10.1002/ijc.32883
pubmed: 31970765
Rosero-Bixby L, Dow WH. Exploring why Costa Rica outperforms the United States in life expectancy: A tale of two inequality gradients. Proc Natl Acad Sci. 2016;113(5):1130–7.
doi: 10.1073/pnas.1521917112
pubmed: 26729886
pmcid: 4747769
Fantin R, Santamaría-Ulloa C, Barboza-Solís C. Social inequalities in cancer survival: A population-based study using the Costa Rican Cancer Registry. Cancer Epidemiol. 2019;2020(65):101695.
Fantin R, Agarwala N, Aparicio A, Pfeiffer R, Waterboer T, Abdelnour A, et al. Estimating the cumulative incidence of SARS-CoV-2 infection in Costa Rica: modelling seroprevalence data in a population-based cohort. Lancet Reg Heal Am. 2023;27:100616.
RAND Corporation. 36-Item Short Form Survey (SF-36). Available from: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form.html .
RAND Corporation. Mental Health Inventory Survey. Available from: https://www.rand.org/health-care/surveys_tools/mos/mental-health.html .
Butt J, Murugan R, Hippchen T, Olberg S, van Straaten M, Wardemann H, et al. From Multiplex Serology to Serolomics-A Novel Approach to the Antibody Response against the SARS-CoV-2 Proteome. Viruses. 2021;13(5):749.
doi: 10.3390/v13050749
pubmed: 33923338
pmcid: 8147094
Farivar SS, Cunningham WE, Hays RD. Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, vol 1. Health Qual Life Outcomes. 2007;5(1):54.
doi: 10.1186/1477-7525-5-54
pubmed: 17825096
pmcid: 2065865
Burholt V, Nash P. Short Form 36 (SF-36) Health Survey Questionnaire: Normative data for Wales. J Public Health (Bangkok). 2011;33(4):587–603.
doi: 10.1093/pubmed/fdr006
Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE open Med. 2016;4:2050312116671725.
doi: 10.1177/2050312116671725
pubmed: 27757230
pmcid: 5052926
Bryson WJ. Long-term health-related quality of life concerns related to the COVID-19 pandemic: a call to action. Qual Life Res. 2021;30:643–5.
doi: 10.1007/s11136-020-02677-1
pubmed: 33073307
Poudel AN, Zhu S, Cooper N, Roderick P, Alwan N, Tarrant C, et al. Impact of Covid-19 on health-related quality of life of patients: A structured review. PLoS One. 2021;16(10):1–20.
doi: 10.1371/journal.pone.0259164
Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mulè G, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2022;28(4):611.e9-611.e16.
Chippa V, Aleem A, Anjum F. Post Acute Coronavirus (COVID-19) Syndrome. StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570608/ .
Apple AC, Oddi A, Peluso MJ, Asken BM, Henrich TJ, Kelly JD, et al. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann Clin Transl Neurol. 2022;9(2):221–6.
doi: 10.1002/acn3.51498
pubmed: 35043593
pmcid: 8862406
Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol. 2021;12:698169.
doi: 10.3389/fmicb.2021.698169
pubmed: 34248921
pmcid: 8260991
Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697–707.
doi: 10.1038/s41586-022-04569-5
pubmed: 35255491
pmcid: 9046077
Fantin R, Brenes-Camacho G, Barboza-Solís C. COVID-19 deaths: Distribution by age and universal medical coverage in 22 countries. Rev Panam Salud Publica/Pan Am J Public Heal. 2021;45:1–9.
doi: 10.26633/RPSP.2021.42